期刊文献+

不同浓度硼替佐米对K562/DNR细胞株NF-κB,IκB及P-gp表达的影响 被引量:4

Effects of different concentrations of bortezomib on the expression of NF-κB,IκB and P-gp of DNR-resistant K562 cells
下载PDF
导出
摘要 目的:观察不同浓度硼替佐米(商品名万珂,PS-341)对柔红霉素(DNR)诱导的K562耐药细胞株(K562/DNR)核因子-κB(NF-κB)、抑制蛋白κB(IκB)及P-糖蛋白(P-gp)表达的影响,探讨PS-341逆转耐药的分子机制.方法:四甲基偶氮唑盐微量酶反应比色法(MTT法)进行耐药细胞株和PS-341细胞毒性的判定.以100mg/LDNR单用或联合应用0.4,4,40μg/LPS-341作用于K562/DNR36h,检测各组NF-κb,IκB及P-gp表达情况,并测定NF-κB活性,检测各组细胞凋亡率.结果:与阴性对照组相比,DNR可诱导NF-κB表达上调、IκB表达下调、P-gp表达上调;加用PS-341可显著抑制NF-κB表达,同时使IκB表达增加、P-gp表达下降,上述作用随PS-341浓度增加而增强.NF-κB活性(%)检测示:DNR组为25.9±2.5,DNR+0.4μg/LPS-341组为20.3±2.0,DNR+4μg/LPS-341组为6.1±2.5,DNR+40μg/LPS-341组为4.6±1.6,加入PS-341后,NF-κB活性受抑,该作用随PS-341浓度增加而增强.细胞凋亡率(%)检测结果示:DNR组为22.5±4.6,DNR+0.4μg/LPS-341组为31.0±5.2,DNR+4μg/LPS-341组为43.6±7.7,DNR+40μg/LPS-341组为56.0±9.3,加入PS-341后可提高DNR引起的细胞凋亡率,该作用随PS-341浓度的增加而增强.结论:PS-341可逆转白血病细胞耐药,该作用呈浓度依赖性. AIM : To observe the effects of bortezomib( PS-341 ) on the expression of NF-κB, IκB and P-gp of K562 cells induced by dannorubicin (K562/DNR). METHODS : MTT method was used to determine the drug-resistant K562 cells and the cellular toxicity of bortezomib; Detect the expression of NF-κB, IκB and P-gp of K562/DNR 36 h after receiving the treatment of 100 mg/L DNR only or added with 0.4,4 and 40 μg/L bortezomib. Detect the apoptosis rate in each group respectively and the activity of NF-κB was detected by ELISA method. RESULTS: Compared with the control group, the expressions of NF-κB and P-gp in K562/DNR group could be induced by DNR. When K562/DNR cells were cultured with bortezomib,the expressions of NF-κB and P-gp induced by DNR were significantly suppressed and IκB was increased, these effects increased with the increase of the concentration of PS-341. The results of NF-κBg activity showed that the team of DNR was 25. 9 ± 2. 5, DNR ± 0.4 μg/L PS-341 was 20.3 ±2.0,DNR ±4 μg/L PS-341was 6.1 ±2.5,DNR ±40 μg/L PS-341 was 4.6 ± 1.6. The activity of NF-κB was suppressed when PS-341 was added in. The results of apoptosis rate ( % ) showed that the team of DNR was 22.5 ± 4.6, DNR ± 0.4 μg/L PS-341 was 31.0 ±5.2,DNR ±4 μg/L PS-341was 43.6 ±7.7, DNR ± 40 μg/L PS-341 was 56.0 ± 9.3. The apoptosis rate increased when K562/DNR cells were cultured with bortezomib, these effects increased with the increase of concentration of bortezomib. CONCLUSION: Bortezomib could convert the cellular drug resistance and this effect showed the characteristic of concentration-dependent pattern.
出处 《第四军医大学学报》 北大核心 2009年第15期1379-1382,共4页 Journal of the Fourth Military Medical University
基金 辽宁省教育厅2006-2007年度高等学校科研项目计划(20060985)
关键词 蛋白酶体抑制剂 NF—κB I-ΚB P-糖蛋白 K562细胞 proteasome inhibitor NF-kappa B I-kappa B P-glycoprotein K562 cells
  • 相关文献

参考文献4

二级参考文献45

  • 1彭也,张晓红.NF-кB信号调节与多发性骨髓瘤治疗新药作用机制的关系[J].国际输血及血液学杂志,2006,29(3):210-212. 被引量:3
  • 2EI-Sabban ME,Nasr R,Dbaibo G,et al.Arsenic-interferon-α-trigge red apoptosis in HTLV-transformed cells is associated with tax down regulation and reversal of NF-κB activation.Blood,2000; 96:2849-2855
  • 3Inoue K,Sugiyama H,Ogawa H,et al.WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.Blood,1994; 84:3071 -3079
  • 4O'Brien M,Kruh GD,Tew KD.The influence of coordinate overexpression of glutathione phase Ⅱ detoxification gene products on drug resistance.J Pharmacol Exp Ther,2000; 294:480-487
  • 5Kurz EU,Leader KB,Kroll DJ,et al.Modulation of human DNA topoisomerase Ⅰ alpha function by interaction with 14-3-3epsilon.J Biol Chem,2000; 275:13948-13954
  • 6Sugiyama H.Wilms' rumor gene WT1:its oncogenic function and clinical application.Int J Hematol,2001; 73:177-187
  • 7Bentires-Alj M,Barbu V,Fillet M,et al.NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells.Oncogene,2003; 22:90-97
  • 8Bosch I,Croop J.P-glycoprotein multidrug resistance and cancer.Biochim Biophys Acta,1996; 1288:F37 -54
  • 9Wang CY,Cusack JC Jr,Liu R,et al.Control of inducible chemoresistance:enhanced anti-rumor therapy through increased apoptosis by inhibitor of NF-κB.Nat Med,1999; 5:412 -417
  • 10Kane RC, Bross PF, Farrell AT, et al. Velcade: U. S. FDA approval for the treatment of multiple myeloma progressing on prior therapy [J ]. Oncologist, 2003, 8(6): 508-13.

共引文献23

同被引文献62

引证文献4

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部